Use access key #2 to skip to page content.
$17.56 -0.42 (-2.34%)
10/10/2008 4:02 PM

Bristol-Myers Squibb Co. (BMY)

CAPS Rating:
****

The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other health care related products.

View All Commentary (BMY)

Recs

7

Avatar proudfather (< 20) Submitted: 6/11/08 6:09 PM : Outperform Start Price: $19.47 BMY Score: 24.53

Bristol Myers is way over-sold at $20. It has not traded below $20 since 1996 and has met resistance at the $20 level on numerous occasions since then. Basic fundamentals are sound. Price/Sales could be a bit lower, but I think the "price" is not the problem, but rather "sales," which seem to have been laging for the past few periods. 1st Qtr '08 financial relults show a 20% increase in sales verses 1st qtr '07. Management reaffirmed 2008 guidance of $1.36 to $1.46 EPS and expects to "grow at a minimum of 15 percent compounded annual growth rate, from the 2007 base through 2010." A strong pipeline should help keep sales up in the coming years. The current dividend yield of 6% is a nice bonus. Should trade between $28.00 and $30.00 in two years.

Report this Post Replies: 2 | Reply

Avatar stockdoc00 (91.46) Submitted: 7/20/08 5:59 PM

Recs: 0 | Rec This

I agree completely. I'm a novice investor but I'm also a physician. Patent expiration on Plavix will hurt a little in the short term but BMY has a very underrated drug pipeline and solid prospects for the future.

Report this Post Reply

Avatar mugwumper12 (99.32) Submitted: 9/25/08 10:51 AM

Recs: 0 | Rec This

Now is a very nice time to be invested in companies paying solid dividends.

Report this Post Reply

Featured Broker Partners